| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0f9a1890fbbe4871e2bba0a9dcb5103 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2020-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfbd05d673c2101875a6e45421431be7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92604e3ba6e1fc3fb4a91548ebdd4041 |
| publicationDate |
2020-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020246281-A1 |
| titleOfInvention |
Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same |
| abstract |
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer. |
| priorityDate |
2016-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |